On December 6, 2024, Abbisko Therapeutics Co., Ltd. (HKEX: 02256) announced that it has delivered an oral presentation of updated phase 1 study results on its independently discovered oral PD-L1 inhibitor, ABSK043, in patients with advanced solid tumors at European Society For Medical Oncology Asia Congress 2024 （“ESMO Asia 2024”）in Singapore.

The results of the study show that at 600mg -1000mg BID, ABSK043 demonstrated a favorable safety profile and impressive anti-tumor activity as a single agent. More prominent efficacy was observed in non-small cell lung cancer （“NSCLC”） patients with high PD-L1 expression, even with EGFR or KRAS mutations and received prior systemic therapies. These findings support a continuing investigation of ABSK043, in EGFR-mutated lung cancers and various other solid tumors.

Abbisko presentation at ESMO Asia 2024:

Presentation Number: 485

Title: Updated Results of Oral PD-L1 Inhibitor ABSK043 in Advanced Solid Tumor Patients (pts) from a Phase 1 Study

Time: December 6, 10:42AM-10:52 AM

About ABSK043

ABSK043 is a novel, orally administered small molecule PD-L1 inhibitor displaying exceptional activity and high selectivity independently discovered and wholly owned by Abbisko Therapeutics. Tumor cells can exploit immune checkpoints such as PD-1 and its ligand PD-L1 to evade immune detection and clearance, thereby suppressing or restricting T-cell responses. ABSK043 selectively binds to the PD-L1 receptor and induces its internalization from the cell surface, effectively inhibiting the PD-1/PD-L1 interaction and alleviating PD-L1-mediated suppression of T-cell activation. In preclinical models, ABSK043 has demonstrated anti-tumor efficacy comparable to approved PD-L1 antibodies. While several PD-1/PD-L1 monoclonal antibodies have been approved worldwide, there are currently no approved orally available PD-1/PD-L1 small molecule drugs. ABSK043 is currently being studied in an ongoing Phase I clinical trial for advanced solid tumors in Australia and China.